Cargando…
Hyperprogressive Disease: Main Features and Key Controversies
Along with the positioning of immunotherapy as a preferential treatment for a wide variety of neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth has been described. This phenomenon has received the name of “hyperprogressive disease”, and several definitions have...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038385/ https://www.ncbi.nlm.nih.gov/pubmed/33916696 http://dx.doi.org/10.3390/ijms22073736 |
_version_ | 1783677363267043328 |
---|---|
author | Arasanz, Hugo Zuazo, Miren Bocanegra, Ana Chocarro, Luisa Blanco, Ester Martínez, Maite Morilla, Idoia Fernández, Gonzalo Teijeira, Lucía Morente, Pilar Echaide, Miriam Castro, Natalia Fernández, Leticia Garnica, Maider Ramos, Pablo Escors, David Kochan, Grazyna Vera, Ruth |
author_facet | Arasanz, Hugo Zuazo, Miren Bocanegra, Ana Chocarro, Luisa Blanco, Ester Martínez, Maite Morilla, Idoia Fernández, Gonzalo Teijeira, Lucía Morente, Pilar Echaide, Miriam Castro, Natalia Fernández, Leticia Garnica, Maider Ramos, Pablo Escors, David Kochan, Grazyna Vera, Ruth |
author_sort | Arasanz, Hugo |
collection | PubMed |
description | Along with the positioning of immunotherapy as a preferential treatment for a wide variety of neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth has been described. This phenomenon has received the name of “hyperprogressive disease”, and several definitions have been proposed for its identification, most of them relying on radiological criteria. However, due to the fact that the cellular and molecular mechanisms have not been elucidated yet, there is still some debate regarding whether this fast progression is induced by immunotherapy or only reflects the natural course of some highly aggressive neoplasms. Moreover, contradictory results of trials including patients with different cancer types suggest that both the incidence, the associated factors and the implications regarding prognosis might differ depending on tumor histology. This article intends to review the main publications regarding this matter and critically approach the most controversial aspects. |
format | Online Article Text |
id | pubmed-8038385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80383852021-04-12 Hyperprogressive Disease: Main Features and Key Controversies Arasanz, Hugo Zuazo, Miren Bocanegra, Ana Chocarro, Luisa Blanco, Ester Martínez, Maite Morilla, Idoia Fernández, Gonzalo Teijeira, Lucía Morente, Pilar Echaide, Miriam Castro, Natalia Fernández, Leticia Garnica, Maider Ramos, Pablo Escors, David Kochan, Grazyna Vera, Ruth Int J Mol Sci Review Along with the positioning of immunotherapy as a preferential treatment for a wide variety of neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth has been described. This phenomenon has received the name of “hyperprogressive disease”, and several definitions have been proposed for its identification, most of them relying on radiological criteria. However, due to the fact that the cellular and molecular mechanisms have not been elucidated yet, there is still some debate regarding whether this fast progression is induced by immunotherapy or only reflects the natural course of some highly aggressive neoplasms. Moreover, contradictory results of trials including patients with different cancer types suggest that both the incidence, the associated factors and the implications regarding prognosis might differ depending on tumor histology. This article intends to review the main publications regarding this matter and critically approach the most controversial aspects. MDPI 2021-04-03 /pmc/articles/PMC8038385/ /pubmed/33916696 http://dx.doi.org/10.3390/ijms22073736 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Arasanz, Hugo Zuazo, Miren Bocanegra, Ana Chocarro, Luisa Blanco, Ester Martínez, Maite Morilla, Idoia Fernández, Gonzalo Teijeira, Lucía Morente, Pilar Echaide, Miriam Castro, Natalia Fernández, Leticia Garnica, Maider Ramos, Pablo Escors, David Kochan, Grazyna Vera, Ruth Hyperprogressive Disease: Main Features and Key Controversies |
title | Hyperprogressive Disease: Main Features and Key Controversies |
title_full | Hyperprogressive Disease: Main Features and Key Controversies |
title_fullStr | Hyperprogressive Disease: Main Features and Key Controversies |
title_full_unstemmed | Hyperprogressive Disease: Main Features and Key Controversies |
title_short | Hyperprogressive Disease: Main Features and Key Controversies |
title_sort | hyperprogressive disease: main features and key controversies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038385/ https://www.ncbi.nlm.nih.gov/pubmed/33916696 http://dx.doi.org/10.3390/ijms22073736 |
work_keys_str_mv | AT arasanzhugo hyperprogressivediseasemainfeaturesandkeycontroversies AT zuazomiren hyperprogressivediseasemainfeaturesandkeycontroversies AT bocanegraana hyperprogressivediseasemainfeaturesandkeycontroversies AT chocarroluisa hyperprogressivediseasemainfeaturesandkeycontroversies AT blancoester hyperprogressivediseasemainfeaturesandkeycontroversies AT martinezmaite hyperprogressivediseasemainfeaturesandkeycontroversies AT morillaidoia hyperprogressivediseasemainfeaturesandkeycontroversies AT fernandezgonzalo hyperprogressivediseasemainfeaturesandkeycontroversies AT teijeiralucia hyperprogressivediseasemainfeaturesandkeycontroversies AT morentepilar hyperprogressivediseasemainfeaturesandkeycontroversies AT echaidemiriam hyperprogressivediseasemainfeaturesandkeycontroversies AT castronatalia hyperprogressivediseasemainfeaturesandkeycontroversies AT fernandezleticia hyperprogressivediseasemainfeaturesandkeycontroversies AT garnicamaider hyperprogressivediseasemainfeaturesandkeycontroversies AT ramospablo hyperprogressivediseasemainfeaturesandkeycontroversies AT escorsdavid hyperprogressivediseasemainfeaturesandkeycontroversies AT kochangrazyna hyperprogressivediseasemainfeaturesandkeycontroversies AT veraruth hyperprogressivediseasemainfeaturesandkeycontroversies |